<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581151</url>
  </required_header>
  <id_info>
    <org_study_id>WE IRB# 11-122</org_study_id>
    <nct_id>NCT01581151</nct_id>
  </id_info>
  <brief_title>Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion</brief_title>
  <official_title>Dexamethasone Implant With Rescue Ranibizumab for Treating Macular Edema Secondary to Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brian Burke, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to compare dexamethasone implant with rescue intravitreal ranibizumab to&#xD;
      monthly intravitreal ranibizumab for the treatment of macular edema secondary to branch or&#xD;
      central retinal vein occlusion. This is based on the null hypothesis that dexamethasone&#xD;
      implant with rescue ranibizumab has inferior best corrected visual acuity at six months&#xD;
      compared to monthly ranibizumab alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) and&#xD;
      Ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA) as needed group:&#xD;
&#xD;
        -  Patients will receive a dexamethasone intravitreal implant injection at day 0. Injection&#xD;
           procedure will be identical to those previously described.8,19,20 Topical tetracaine&#xD;
           drops will be given, a lid speculum inserted, and then 5% povidone iodine drops will be&#xD;
           given. After subconjunctival injection of 2% lidocaine, the 0.7mg DEX implant will be&#xD;
           inserted through the pars plana using a customized, single use, 22-gauge applicator.&#xD;
           Patients will be treated with topical ophthalmic antibiotics four times daily for three&#xD;
           days after the procedure.&#xD;
&#xD;
        -  During monthly visits 1,2,3, and 5, patients will receive a ranibizumab intravitreal&#xD;
           injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥&#xD;
           250 μm or the best-corrected visual acuity is 20/40 or worse. The injection procedure is&#xD;
           described in the next section.&#xD;
&#xD;
        -  During monthly visit 4, patients will receive a dexamethasone intravitreal implant&#xD;
           injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥&#xD;
           250 μm or the best-corrected visual acuity is 20/40 or worse.&#xD;
&#xD;
      Monthly Ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA) group:&#xD;
&#xD;
        -  Patients will receive a ranibizumab intravitreal injection on day 0. During each other&#xD;
           visit, patients will receive a ranibizumab intravitreal injection. The protocol will use&#xD;
           the term &quot;monthly&quot; to represent a 30 day interval between treatments. The minimal&#xD;
           interval between treatments may be 25 days.&#xD;
&#xD;
        -  Injection procedures will be identical to those previously described.8,19,20 Topical&#xD;
           tetracaine drops will be given, a lid speculum inserted, and then 5% povidone iodine&#xD;
           drops will be given. After subconjunctival injection of 2% lidocaine, a 30-gauge needle&#xD;
           will be inserted through the pars plana, and 0.5 mg (0.05mL) of drug injected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>6 months</time_frame>
    <description>• Primary outcome: Mean change from baseline in best corrected visual acuity score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Foveal Thickness</measure>
    <time_frame>6 months</time_frame>
    <description>Mean absolute change from baseline in central foveal thickness,&#xD;
Proportion of subjects with a central foveal thickness 250m&#xD;
Mean change in fluid and central foveal thickness on OCT Time Frame&#xD;
Proportion of subjects who gain at least 15 letters in BCVA score&#xD;
Proportion of subjects who lose fewer than 15 letters in BCVA score&#xD;
The incidence of ocular and systemic adverse events&#xD;
Mean change from baseline in the NEI VFQ 25 near activities&#xD;
Mean change from baseline in the NEI VFQ 25 distance activities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Monthly Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• Patients will receive a ranibizumab intravitreal injection on day 0. During each other visit, patients will receive a ranibizumab intravitreal injection. The protocol will use the term &quot;monthly&quot; to represent a 30 day interval between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone intravitreal implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a dexamethasone intravitreal implant injection at day 0.&#xD;
During monthly visits 1,2,3, and 5, patients will receive a ranibizumab intravitreal injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse. The injection procedure is described in the next section.&#xD;
During monthly visit 4, patients will receive a dexamethasone intravitreal implant injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intravitreal implant</intervention_name>
    <description>Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.</description>
    <arm_group_label>Dexamethasone intravitreal implant</arm_group_label>
    <other_name>Ozurdex - Allergan</other_name>
    <other_name>Ranibizumab - Genentech</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monthly Ranibizumab</intervention_name>
    <description>30 days between treatments</description>
    <arm_group_label>Monthly Ranibizumab</arm_group_label>
    <other_name>Ranibizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  18 to 90 year-old men or women&#xD;
&#xD;
          -  Women must be postmenopausal for at least 12 months before study enrollment, or&#xD;
             surgically sterile. Potential child bearing women must have a negative serum pregnancy&#xD;
             test within 14 days prior to the first treatment and practice effective contraception&#xD;
             during and at least 120 days following the last dose of injection.&#xD;
&#xD;
          -  Patient of the Wills Eye Institute Retina service, including all Mid-Atlantic Retina&#xD;
             offices.&#xD;
&#xD;
          -  Healthy enough to participate in the study.&#xD;
&#xD;
          -  Willing and able to consent to participation in the study.&#xD;
&#xD;
          -  Retinal vein occlusion:&#xD;
&#xD;
          -  Must be diagnosed within two weeks of onset of symptoms&#xD;
&#xD;
          -  Best Corrected Visual Acuity (BCVA) on initial presentation between 20/40 and 20/320&#xD;
&#xD;
          -  No contraindications to intravitreal injection of dexamethasone implant or ranibizumab&#xD;
&#xD;
          -  Central foveal thickness greater than 250 m on Spectral Domain-OCT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unknown duration of symptoms prior to diagnosis.&#xD;
&#xD;
          -  Patients with any history of prior intravitreal dexamethasone or anti-VEGF or grid&#xD;
             laser.&#xD;
&#xD;
          -  Patients with diabetic retinopathy.&#xD;
&#xD;
          -  Patients with age-related macular degeneration.&#xD;
&#xD;
          -  Patients with an optic neuropathy.&#xD;
&#xD;
          -  Patients with a retinal detachment or history of retinal detachment.&#xD;
&#xD;
          -  Patients with a significant epiretinal membrane.&#xD;
&#xD;
          -  Patients with a history of choroidal neovascularization.&#xD;
&#xD;
          -  Patients with glaucoma with visual field loss documented on a Humphrey Visual Field&#xD;
             test or ocular hypertension requiring more than 2 medications to control IOP in the&#xD;
             study eye.&#xD;
&#xD;
          -  Patients with a clinically significant media opacity.&#xD;
&#xD;
          -  Patients using or anticipating using systemic steroids.&#xD;
&#xD;
          -  Patients with any uncontrolled systemic disease.&#xD;
&#xD;
          -  Patients with aphakia or anterior-chamber intraocular lens.&#xD;
&#xD;
          -  Patients with active neovascularization of the iris, disc, or retina.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brianna Kenney</last_name>
    <email>research@midatlanticretina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wills Eye Retina Service</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Jordan</last_name>
      <phone>215-928-3092</phone>
      <email>research@midatlanticretina.com</email>
    </contact>
    <investigator>
      <last_name>Julia A. Haller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allen Chiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ehsan Rahimy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allen Ho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sunir Garg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl Regillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Spirn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Mehta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Brian Burke, MPH</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>retinal vein occlusion</keyword>
  <keyword>ozurdex</keyword>
  <keyword>lucentis</keyword>
  <keyword>BCVA</keyword>
  <keyword>foveal thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

